$LRCX

BRANDT ERIC sold $20.0M of LRCX

BRANDT ERIC sold 54,500 shares of LAM RESEARCH CORP (LRCX) at an average of $367.18 ($355.71–$373.09, $20.01M total) across 17 trades on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BRANDT ERIC
Published Jun 15, 2026, 11:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRCX
Neutral
medium confidence
Mentioned
$LRCX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRCXNeutralLow
01

Why it matters

A director’s open-market sale totaling ~$20.0M could slightly pressure sentiment, but the presence of a 10b5-1 plan typically lowers interpretive weight versus discretionary selling.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce new fundamental information.

03

What to watch

The article provides only the sale details; it does not include any concurrent buys, changes in guidance, or new company fundamentals that would drive a stronger repricing.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-15; transaction dated 2026-06-12.

Background

The article is an SEC Form 4 insider transaction disclosure for LAM RESEARCH CORP (LRCX).

Company-level read

Ticker impact

$LRCXNeutralMedium confidence
Context

SEC Form 4 shows LRCX director BRANDT ERIC sold about 54,500 shares in an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with a pre-arranged 10b5-1 plan; no new operational, financial, or regulatory facts are disclosed.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • LAM RESEARCH CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • BRANDT ERIC

    Director who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BACMed

US Futures Hold Steady Ahead of Inflation Report

US stock futures were stable on Wednesday ahead of the September inflation report. Bank of America shares fell over 2% after $1.2B in penalties from regulators. Memory stocks declined due to AI investment concerns and Chinese competition, with Micron down 4.6%. Financial stocks also dropped post-earnings, including Citigroup (-5.3%) and Wells Fargo (-2.6%).

$LRCXLow

Round Design Infringement Case Against Lam Research < Supply Chain < 기사본문

BCNC, a South Korean semiconductor component maker, was ordered by a Seoul court to stop producing and distributing certain edge-ring products, pay damages, and destroy existing inventory, following a design-right infringement lawsuit by Lam Research. The court partially dismissed Lam Research's claims. Both companies are also involved in separate patent disputes, with mixed rulings. BCNC plans to appeal the decision.

$LRCXMedAI 8/10

Lam Research Stocks Fall 2.1% as AI Spending Lifts Target 33%

Lam Research (LRCX) shares fell 2.42% to $325.81 on October 7, despite Cantor Fitzgerald raising its price target to $425 from $320. The company reported June-quarter revenue of $6.72 billion, up 15.1% from the prior quarter, with improved margins. Cantor's target suggests 30.4% upside, but shares are 106.68% above GF Value™ estimate of $157.64.

$LRCXHigh

TSMC Stock Hits Record High, Morgan Stanley Raises Lam Research Price Target

TSMC (TSM) stock hit a record high, nearing a $2.5T market cap, driven by AI chip demand. Morgan Stanley raised Lam Research's (LRCX) price target to $385, citing its share gains in advanced logic and expected December-quarter revenue of $9B, above consensus. The bank sees LRCX as a key beneficiary of TSMC's 2nm process advancements and increased capital expenditure share.